Based on these findings, we hypothesized that deletion of GCTB-OCs by denosumab might decrease the level of sFRP in tumor tissues, activate a cascade of Wnt-5a/Ror2/Rac1 signaling, and finally cause the osteoblastic differentiation of GCTB-SCs. This evidence concerns the gene RAC1 and neoplasm.